Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Denosumab, sold under the trade name Prolia among others, as well as many biosimilars, is a human monoclonal antibody used for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.
Read the full article on WikipediaGiant cell tumour of bone Clinical criteria: Patient must be one in whom surgical resection is not feasible; OR Patient must be one in whom surgical resection is possible but surgery would result in significant morbidity. Population criteria: Patient must be an adult; OR Patient must be a skeletally mature adolescent. Treatment criteria: Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
Bone metastases Clinical criteria: The condition must be due to breast cancer. Treatment criteria: Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
Osteoporosis Clinical criteria: Population criteria: Patient must be aged 70 years or older. Patient must have a Bone Mineral Density (BMD) T-score of -2.5 or less, AND Patient must not receive concomitant treatment with any other PBS-subsidised anti-resorptive agent for this condition. The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.
Established osteoporosis Clinical criteria: Patient must have fracture due to minimal trauma, AND Patient must not receive concomitant treatment with any other PBS-subsidised anti-resorptive agent for this condition. The fracture must have been demonstrated radiologically and the year of plain x-ray or computed tomography (CT) scan or magnetic resonance imaging (MRI) scan must be documented in the patient's medical records when treatment is initiated. A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.
“Bone remodeling is the process by which the body continuously removes old bone tissue and replaces it with new bone.[citation needed] It is driven by various types of cells, most notably osteoblasts (which secrete new bone) and osteoclasts (which break down bone); osteocytes are also present in bone.[citation needed]”
Working under the parallel aged-care framework? Aged-care equivalent →